NEW YORK, NY– Faruqi & Faruqi, LLP, a leading national securities law firm, announces that it has been appointed as Lead Counsel in DeSmet v. Intercept Pharmaceuticals, Inc., et al., No. 1:17-cv-07371-LAK, a class action alleging violations of the federal securities laws against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) and certain of the Company’s officers and directors.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company’s lead product candidate Ocaliva, a bile acid analog for the treatment of primary biliary cholangitis (“PBC”), entailed undisclosed safety risks, including death, to patients suffering from PBC; and (ii) as a result, Intercept’s public statements were materially false and misleading at all relevant times.

Continue reading Court Appoints Faruqi & Faruqi, LLP As Lead Counsel For Class Action Against Intercept Pharmaceuticals, Inc at STL.News.